** Shares of biopharmaceutical group HUTCHMED (China) Ltd 0013.HK jump 9.7% to HK$26, their highest since April 2
** Stock on course for third consecutive session of gains
** HUTCHMED and Іnnovent Biologics 1801.HK say in a joint statement that China National Medical Products Administration (NMPA) has accepted for review the New Drug Application for the combination of fruquintinib and sintilimab for treatment of renal cell carcinoma in kidney cancer
** Fruquintinib is co-developed and co-commercialized in China by HUTCHMED and Eli Lilly LLY.N
** Sintilimab is co-developed and co-commercialized by Іnnovent and Eli Lilly
** Hong Kong's healthcare index .HSCIH falls 1.6%, Hang Seng Biotech Index .HSHKBIO drops 1.8%
** YTD, HUTCHMEd stock up 5.8%
(Reporting by Donny Kwok)
((donny.kwok@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。